AVASTIN

LOE ApproachingmAb

bevacizumab

BLAINTRAVENOUSVIALPriority Review
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
121

Mechanism of Action

Vascular Endothelial Growth Factor-directed Antibody Interactions

Pharmacologic Class:

Vascular Endothelial Growth Factor Inhibitor

Clinical Trials (5)

NCT07284849Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Started Mar 2026
700 enrolled
CRC (Colorectal Cancer)
NCT07323576Phase 2Withdrawn

A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

Started Feb 2026
0
Colorectal Cancer
NCT07416058Phase 2Not Yet Recruiting

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Started Jan 2026
NCT07059494Phase 4Recruiting

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

Started Jan 2026
40 enrolled
Hepatocellular Carcinoma
NCT07221357Phase 2/3Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Started Dec 2025
990 enrolled
Untreated, Unresectable, or Metastatic Colorectal Cancer